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<RH>Letter to the Editor 
Letter to the Editor 
Myelodysplasia in a psoriasis patient receiving etanercept: Cause or coincidence? 
Sir, 
Myelodysplastic syndrome comprises hemopoietic insufficiency, often associated with 
cytopenias of one or more cell lineages that may lead to leukemic transformation.1 Here, we 
report a case of myelodysplastic syndrome in a psoriatic patient following therapy with tumour 
necrosis factor-α blocking agent (etanercept). 
A 76-year-old male patient presented with psoriasis vulgaris since the last 20 years without any 
arthritis. He was treated with subcutaneous etanercept, 50 mg twice a week for 6 months 
followed by once a week for another 6 months, to achieve Psoriasis Area and Severity Index 90 
(PASI90) at 6 months. Prior to etanercept he had been treated with topical steroids, topical 
vitamin D analogues, 6-month course of narrow-band-ultraviolet-B and 1-year acitretin without 
any appreciable benefit.   
After one year of etanercept therapy, the patient presented to our emergency unit with 
spontaneous bluish bruising (ecchymosis) and recurrent epistaxis. A complete blood count 
recorded critically low platelet count (23 × 109/L), anemia (11.7 g/dl) and normal leukocyte 
count (6.6 × 109/L), with 0.5 × 109/L monocytes and 2% blasts [Figure 1]. Reticulocyte count 
was 136 × 103 cells/mm3, 3.4% (N = 0.8–2.5%) with low reticulocyte index, serum ferritin was 
1280 ng/ml (N = 21.8–274.7 ng/ml) and folate was low at 1.7 ng/ml (N = 7–31.4 ng/ml), which 
indicated ineffective erythropoiesis. (Table 1)  
Bone marrow aspirate [Figure 2] and biopsy [Figure 3] revealed hypercellularity. Blast cells 
accounted for almost 8% of the total nucleated marrow cells. The majority of neutrophils were 
hypogranular. Hypolobulated megakaryocytes were observed. Reticulin fibres were not 
increased.  
Peripheral blood also revealed bicytopenia, blasts and 0.5 × 109/L monocytes. Bone marrow 
showed 8% trilineage dysplasia and blasts. A diagnosis of myelodysplastic syndrome with 
excess blasts-1was made based on the hematologic picture. 
We stopped etanercept treatment and administered two cycles of azacitidin and folic acid 
supplementation, with almost no response and even worsening of platelet count (17 × 109/L) and 
hemoglobin (8.3 g/dl). While he was waiting for the third cycle, he was admitted to the 
emergency unit suffering from lower gastrointestinal bleeding, epistaxis and shock. The patient 
expired eventually due to cardiopulmonary arrest. 
Immune dysregulation and altered T-cell hemostasis are essential factors for the development 
of myelodysplastic syndrome. Several authors have reported a higher risk of myelodysplastic 
syndrome in patients suffering from autoimmune disorders, resulting from chronic 
overproduction of apoptosis inducing cytokines  like tumor necrosis factor-alpha. It has been 
proven that accelerated apoptosis of bone marrow cells accounts for the disturbed hemopoiesis 
and peripheral blood cytopenias leading to myelodysplastic syndrome, despite the presence of 
hypercellular bone marrow.1 In addition, nonspecific activation and proliferation of T 
lymphocytes seen in myelodysplastic syndrome has been documented to promote epidermal 
growth in genetically susceptible psoriasis patients.2 
Myelodysplastic syndrome may be associated with psoriasis in about 7% of cases.3 Özbek et al. 
reported a 3.5-year-old girl with psoriasis, hypogammaglobulinemia and pancytopenia who 
developed myelodysplastic syndrome-excess blasts that progressed to acute myeloid leukemia.2 
Moreover, Maleszka et al. noted increased incidence of leukemia and laryngeal cancer among 
families of psoriasis patients.4 In addition, there are some reported cases of leukemia that 
developed in psoriasis patients receiving systemic immunosuppressives (cyclosporine, 
methotrexate and etanercept). However, the association of leukemia and psoriasis is not well-
investigated.4 
Etanercept may induce various hematological side effects including pancytopenia and aplastic 
anaemia, as reported by the US Food and Drug Administration.5 Tumor necrosis factor-alpha 
enforces apoptosis of tumor cells and promotes different antitumor activities like activation of 
natural killer cells, stimulation of CD8 cells and acceleration of camptothecan and etoposide 
antitumor effect. Loss of such activities may mediate tumor growth in acute and chronic myeloid 
leukemia.6 
Tumor necrosis factor-alpha is also inhibitory to hematopoietic stem cells. Studies have shown 
increased levels of tumor necrosis actor-alpha in myelodysplastic syndrome marrow. Thus, 
antagonizing it significantly enhances in-vitro hematopoietic colony formation. Deeg et al. tried 
to treat myelodysplastic syndrome with etanercept as a pilot trial.7 However, their study found 
limited favorable response in some patients and worsening of blood cell counts in others. The 
findings of Deeg et al. and the contradictory effects of tumor necrosis factor-alpha on dysplastic 
bone marrow suggest that tumor necrosis factor-alpha is only partially accountable for the 
dysregulated hemopoiesis in myelodysplastic syndrome; thus there are various other 
pathomechanisms for myelodysplastic syndrome.7  
Only three cases of myelodysplastic syndrome have been reported till date in psoriasis patients 
following etanercept therapy, ours being the 4th case. Nair et al. reported the case of a 57-year-
old man with psoriatic arthritis who developed myelodysplasia that progressed to acute myeloid 
leukemia after 6 months of etanercept treatment.6 Bachmeyer et al.8 and Knudson et al.9 reported 
the cases of 40 and 43-year-old psoriatic males who were diagnosed with myelodysplastic 
syndrome after 4 and 14 months of etanercept therapy, respectively. The case reported by 
Knudson et al.  had progressed to acute myeloid leukemia followed by death.9 In addition to the 
aforementioned cases, another case was reported by Bakland and Nossent where a 31-year-old 
female with ankylosing spondylitis developed acute myeloid leukemia 4 months after etanercept 
treatment.5 In our case, myelodysplasia with excess blasts developed 1 year after initiating 
etanercept therapy.  
Taken together, the current case adds to the growing evidence that suggests a link between 
myelodysplastic syndrome and etanercept treatment in psoriasis patients. Pre-treatment 
thrombocytopenia was seen in our patient (131 × 109/L) and the patient reported by Knudson et 
al.  patient (126 × 109/L)9, while mild leucopenia (3.6 × 109/L) was reported by Bakland and 
Nossent before initiation of etanercept.5 More studies are needed to clarify whether this was an 
accidental association or etanercept may aggravate myelodysplasia in all susceptible patients.  
Although progressive and critical worsening of blood counts following etanercept treatment may 
demonstrate its aggressive hematologic and myelodysplastic adverse events, the susceptibility of 
psoriasis patients to myelodysplasia cannot be ruled out. Therefore, the present case and 
literature review support the need for pharmacovigilance, prospective cohort or retrospective 
case-control studies to prove or disprove this association.  
In conclusion, psoriatic patients being treated with etanercept should be considered at dual risk 
of developing myelodysplastic syndrome – therapy-related and autoimmunity-associated. Hence, 
we recommend that psoriatic patients who are receiving etanercept should be followed regularly 
by routine blood counts and it should be discontinued upon onset of any cytopenias. 
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Table 
Table 1: Retrospective analysis for complete blood count of the reported case 
CBC (reference range 
and unit) 
Baseline During etanercept 
treatment 
After stoppage of etanercept 
1 
month 
With use of azacitidine 
6 
months 
12 
months 
2 months 4 
months 
Hemoglobin (14.0–18.0 
g/dl) 
17.6 15.8 11.7 11.0 9.2 8.3 
White blood cells (3.0–
11.0×109/L) 
9.4 6.0 6,6 21.0 9.0 7.3 
Neutrophils (2.0–
7.0×109/L) 
6.5 4.0 4.9 16.0 6.8 3.8 
Lymphocytes 
(1.0–3.0×109/L) 
1.1 0.9 0.9 2.5 0.9 1.7 
Monocytes (0.2–
1.0×109/L) 
1.2 0.9 0.5 0.8 0.9 0.9 
Eosinophils 
(0.02–0.5×109/L) 
0.01 0.0 0.0 0.0 0.0 0.03 
Basophils (0.02–
0.1×109/L) 
0.64 0.2 0.1 1.3 0.2 0.65 
Blast (0.0×109/L) 0.0 0.0 0.1 0.4 0.2 0.2 
Platelet (150–
450×109/L) 
131 70 23 23 17 17 
CBC: Complete blood count 
 
 
Figure Legends 
Figure 1a: Peripheral blood smear showing monocytes (black arrow) (×100) 
Figure 1b: Peripheral blood smear showing blast cells (red arrow) (oil immersion) (×100) 
Figure 2: Bone marrow smear showing hypercellular bone marrow with hypolobated 
megakaryocytes (arrow and inset × oil immersion) (×400 40) 
Figure 3: Bone marrow trephine biopsy showing hypolobated megakaryocyte (red arrow) and a 
cluster of abnormal localization of immature precursors (blue arrow) (×400 40) 
